0001140361-22-018639 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2022	May 06, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	0-51481
Entity Registrant Name	STRATA SKIN SCIENCES, INC.
Entity Central Index Key	0001051514
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3986004
Entity Address, Address Line One	5 Walnut Grove Drive
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	Horsham
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19044
City Area Code	215
Local Phone Number	619-3200
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	SSKN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,723,046

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,923	$ 12,586
Accounts receivable, net of allowance for doubtful accounts of $288 and $275 at March 31, 2022 and December 31, 2021, respectively	2,972	3,433
Inventories	4,758	3,489
Prepaid expenses and other current assets	393	462
Total current assets	19,046	19,970
Property and equipment, net	6,921	6,883
Operating lease right-of-use assets	549	638
Intangible assets, net	19,568	10,083
Goodwill	8,803	8,803
Other assets	200	216
Total assets	55,087	46,593
Current liabilities:
Accounts payable	3,970	2,822
Accrued expenses and other current liabilities	6,539	6,377
Deferred revenues	3,121	3,285
Current portion of operating lease liabilities	289	318
Current portion of contingent consideration	500	0
Total current liabilities	14,419	12,802
Long-term debt	7,356	7,319
Deferred revenues and other liabilities	320	400
Deferred tax liability	266	266
Operating lease liability, net of current portion	324	392
Contingent consideration, net of current portion	8,622	0
Total liabilities	31,307	21,179
Commitments and contingencies (Note 14)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized; 34,723,046, and 34,364,679, shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	35	34
Additional paid-in capital	247,926	247,059
Accumulated deficit	(224,181)	(221,679)
Total stockholders' equity	23,780	25,414
Total liabilities and stockholders' equity	$ 55,087	$ 46,593

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Allowance for doubtful accounts	$ 288	$ 275
Stockholders' equity:
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	0
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	34,723,046	34,364,679
Common stock, shares outstanding (in shares)	34,723,046	34,364,679

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Condensed Consolidated Statements of Operations [Abstract]
Revenues, net	$ 7,041	$ 5,827
Cost of revenues	2,913	2,114
Gross profit	4,128	3,713
Operating expenses:
Engineering and product development	163	384
Selling and marketing	3,616	2,932
General and administrative	2,652	2,789
Total operating expenses	6,431	6,105
Loss from operations	(2,303)	(2,392)
Other income (expense):
Interest expense	(199)	(30)
Interest income	0	8
Other income (expense), net	(199)	(22)
Income (loss) before income taxes	(2,502)	(2,414)
Income tax expense	0	(4)
Net loss	$ (2,502)	$ (2,418)
Net loss per share of common stock - basic (in dollars per share)	$ (0.07)	$ (0.07)
Net loss per share of common stock - diluted (in dollars per share)	$ (0.07)	$ (0.07)
Weighted average shares of common stock outstanding - basic (in shares)	34,679,246	33,802,129
Weighted average shares of common stock outstanding - diluted (in shares)	34,679,246	33,802,129

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2020	$ 34	$ 244,831	$ (218,973)	$ 25,892
Beginning balance (in shares) at Dec. 31, 2020	33,801,045
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	662	0	662
Issuance of restricted stock	$ 0	0	0	0
Issuance of restricted stock (in shares)	16,260
Net loss	$ 0	0	(2,418)	(2,418)
Ending balance at Mar. 31, 2021	$ 34	245,493	(221,391)	24,136
Ending balance (in shares) at Mar. 31, 2021	33,817,305
Beginning balance at Dec. 31, 2021	$ 34	247,059	(221,679)	25,414
Beginning balance (in shares) at Dec. 31, 2021	34,364,679
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	368	0	368
Issuance of common stock for acquisition	$ 1	499	0	500
Issuance of common stock for acquisition (in shares)	358,367
Net loss	$ 0	0	(2,502)	(2,502)
Ending balance at Mar. 31, 2022	$ 35	$ 247,926	$ (224,181)	$ 23,780
Ending balance (in shares) at Mar. 31, 2022	34,723,046

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,502)	$ (2,418)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Amortization of intangible assets	696	352
Amortization of right-of-use assets	89	86
Depreciation	625	481
Amortization of deferred financing costs and debt discount	37	0
Provision for (recoveries of) doubtful accounts	13	(54)
Stock-based compensation	368	662
Loss on disposal of property and equipment	17	0
Deferred taxes	0	4
Changes in operating assets and liabilities:
Accounts receivable	448	145
Inventories	(1,198)	132
Prepaid expenses and other assets	85	(65)
Accounts payable	1,148	387
Accrued expenses and other liabilities	175	586
Deferred revenues	(257)	(54)
Operating lease liabilities	(97)	(91)
Net cash (used in) provided by operating activities	(353)	153
Cash flows from investing activities:
Purchase of property and equipment	(679)	(740)
Cash paid in connection with TheraClear asset acquisition	(631)	0
Net cash used in investing activities	(1,310)	(740)
Net decrease in cash, cash equivalents and restricted cash	(1,663)	(587)
Cash, cash equivalents and restricted cash, beginning of period	12,586	18,112
Cash, cash equivalents and restricted cash, end of period	10,923	17,525
Cash and cash equivalents	10,923	10,043
Restricted cash	0	7,482
Supplemental disclosure of cash flow information:
Cash paid for interest	160	30
Supplemental disclosure of non-cash operating, investing and financing activities:
Inventories acquired in connection with TheraClear asset acquisition	71	0
Intangible assets acquired in connection with TheraClear asset acquisition	10,182	0
Contingent consideration issued in connection with TheraClear asset acquisition	9,122	0
Common stock issued in connection with TheraClear asset acquisition	$ 500	$ 0

The Company

3 Months Ended

Mar. 31, 2022

The Company [Abstract]

The Company

Note 1

The Company:

Background

STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear acne treatment device to broaden its opportunities with expansion potential in the acne care market.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC excimer laser system received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of March 31, 2022, there were 903 XTRAC systems placed in dermatologists’ offices in the United States and 55 systems internationally under the Company’s recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments, which if exceeded would incur additional fees. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer, which includes system maintenance and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.

Since 2019, the Company has been transitioning its international dermatology procedures equipment sales through its master distributor to a direct distribution model for equipment sales and recurring revenue on a country-by-country basis, primarily in the Middle East and Asia.

In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which became a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains, constrained work force participation and created significant volatility and disruption of financial markets. In addition, the pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices which are our primary customers. While most offices reopened, some practices closed and never reopened, and the ongoing impact of the COVID-19 pandemic and its variants on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames will depend on future developments, including the duration and ongoing spread of the COVID-19 outbreak and its variants, continued or renewed restrictions on business operations and transportation, any governmental and societal responses thereto, including legislative or regulatory changes as well as the percentage of the populace vaccinated and the effectiveness of COVID-19 vaccines and the continued impact on worldwide economic and geopolitical conditions, all of which are uncertain and cannot be predicted.

Domestically, as the procedures for which the Company’s devices are used are elective in nature; and as social distancing, travel restrictions, and other restrictions became prevalent in the United States, this had a negative impact on the Company’s recurring revenue model and its financial position and cash flow. The virus has disrupted the supply chains world-wide which the Company depends upon to provide a steady source of components to manufacture and repair the Company’s devices. To mitigate the impact of COVID-19 the Company took a variety of measures to ensure the availability and functioning of its critical infrastructure by implementing business continuity plans. To promote the safety and security of its employees, while complying with various government mandates including work-from-home arrangements and social-distancing initiatives to reduce the transmission of COVID-19, the Company is complying with federal and local regulations at its facilities. In addition, the Company created and executed programs utilizing its direct-to-consumer advertising and call center to contact patients and partner clinics to restart the Company’s partners’ businesses. In October 2021, the Company implemented a policy whereby all Company employees are required to be vaccinated or complete weekly COVID-19 testing. See Note 2, Liquidity for discussion on Company liquidity.

Supply chain disruptions which began during the pandemic have continued and may continue for the foreseeable future. While the Company’s operations have not been materially impacted by the general trends in supply chain problems, the Company continues to monitor and assess potential risks.

Basis of Presentation:

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned, inactive subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. These condensed consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”), and other forms filed with the SEC from time to time. Dollar amounts included herein are in thousands, except share, per share data and number of lasers.

Reclassifications

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s stockholders’ equity, results of operations, or cash flows.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the Company’s 2021 Form 10-K, and there have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2022.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of March 31, 2022, the more significant estimates include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of acquired intangible assets, state sales and tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets.

Fair Value Measurements

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

	•	Level 1 – quoted market prices in active markets for identical assets or liabilities.
	•	Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

The fair values of cash and cash equivalents and restricted cash are based on their respective demand values, which are equal to the carrying values. The carrying values of all short-term monetary assets and liabilities are estimated to approximate their fair values due to the short-term nature of these instruments. As of March 31, 2022 and December 31, 2021, the carrying value of the Company’s current Senior Term Facility approximated its fair value due to its variable interest rate.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. The activity in the warranty accrual during the three months ended March 31, 2022 and 2021 is summarized as follows:

	Three Months Ended, March 31,
	2022			2021
Balance, beginning of period	$	79		$	113
Additions		34			4
Expirations and claimed satisfied		(14	)		(32	)
Total		99			85
Less current portion within accrued expenses and other current liabilities		(66	)		(63	)
Balance within deferred revenues and other liabilities	$	33		$	22

Net Loss Per Share

Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	March 31,
	2022		2021
Unvested restricted stock units		89,681		-
Stock options		4,434,714		6,925,478
Common stock warrants		373,626		-
Total		4,898,021		6,925,478

Accounting Pronouncements Recently Adopted

In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, Earnings per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges or Freestanding Equity-Classified Written Call Options. The pronouncement outlines how an entity should account for modifications made to equity-classified written call options, including stock options and warrants to purchase the entity’s own common stock. The guidance in the ASU requires an entity to treat a modification of an equity-classified written call option that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the equity-classified written call option or as termination of the original option and issuance of a new option. The guidance is effective prospectively for fiscal years beginning after December 15, 2021. The adoption of this guidance on January 1, 2022 did not have a material effect on the condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended subsequently by ASUs 2018-19, 2019-04, 2019-05, 2019-10, 2019-11 and 2020-03. The guidance in the ASUs requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used. The standard also establishes additional disclosures related to credit risks. This standard is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company does not believe this will have a material effect on its condensed consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. These pronouncements provide temporary optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships to ease the financial reporting burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. The transition period for adopting these ASUs is March 2020 through December 31, 2022. The Company continues to evaluate the temporary expedients and options available under this guidance and the effects of these pronouncements and, as the Company does not have any hedging activities, does not believe this will have a material effect on its condensed consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share (EPS) calculations in certain areas. The guidance is effective beginning after December 15, 2023 and early adoption is permitted. The Company does not currently engage in contracts covered by this guidance and does not believe it will have a material effect on the Company’s condensed consolidated financial statements, but it could in the future.

Liquidity	3 Months Ended
Liquidity	Mar. 31, 2022
Liquidity [Abstract]
Liquidity	Note 2 Liquidity: The Company has been negatively impacted by the ongoing COVID-19 pandemic, has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate and refinanced its debt at a lower interest rate. During the COVID-19 pandemic, the Company received cash proceeds from a Paycheck Protection Program (“PPP”) loan, which was forgiven, and an Economic Injury Disaster Loan (the “EIDL loan”) that was repaid at the time the Senior Term Facility was entered into with MidCap Financial Trust in September 2021 (Note 9). Additionally, in October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to $11.0 million of its common stock in registered “at-the-market” offerings. Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of its products, will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these unaudited interim condensed consolidated financial statements. However, the negative impact of the ongoing COVID-19 outbreak on the financial markets and supply chain disruptions could interfere with the Company’s ability to access financing and on favorable terms.

Revenue Recognition

3 Months Ended

Mar. 31, 2022

Revenue Recognition [Abstract]

Revenue Recognition

Note 3

Revenue Recognition:

Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term period specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

	•	identification of the contract, or contracts, with a customer;
	•	identification of the performance obligations in the contract;
	•	determination of the transaction price;
	•	allocation of the transaction price to the performance obligations in the contract; and
	•	recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of March 31, 2022:

Remaining 2022	$	1,263
2023		1,624
2024		1,303
2025		530
2026		4
Total	$	4,724

Remaining performance obligations related to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties but exclude any equipment accounted for as leases. As of March 31, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $21, and the Company expects to recognize $10 of the remaining performance obligations within one year and the balance over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.

Contract liabilities primarily relate to extended warranties where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of stand-alone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of March 31, 2022, the $10 of short-term contract liabilities is presented as deferred revenues and the $11 of long-term contract liabilities is presented within deferred revenues and other liabilities on the condensed consolidated balance sheet. For the three months ended March 31, 2022 and 2021, the Company recognized $5 and $34, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2021 and 2020.

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Acquisition of TheraClear Assets

3 Months Ended

Mar. 31, 2022

Acquisition of TheraClear Assets [Abstract]

Acquisition of TheraClear Assets

Note 4

Acquisition of TheraClear Assets:

In January 2022, the Company acquired certain assets related to the TheraClear Devices from Theravant Corporation (“Theravant”). The TheraClear asset acquisition will allow the Company to further develop, commercialize and market the TheraClear Devices that are used for acne treatment, as well as advance the TheraClear technology into multiple other devices that can be used to treat a range of additional indications.

The Company made an upfront cash payment of $500 and issued to Theravant 358,367 shares of common stock with an aggregate value of $500 as of the closing date in connection with the TheraClear asset acquisition. Theravant is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones, up to $20.0 million in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $1.0 million in future milestone payments upon the achievement of certain development and commercialization related targets.

The Company determined this transaction represented an asset acquisition as substantially all of the value was in the TheraClear technology intangible asset as defined by ASC 805, Business Combinations.

The purchase price was allocated, on a relative fair basis, to the technology intangible asset and acquired inventories as follows:

Consideration:
Cash payment	$	500
Common stock issued		500
Transaction costs		131
Contingent consideration		9,122
Total consideration	$	10,253

Assets acquired:
Technology intangible asset	$	10,182
Inventories		71
Total assets acquired	$	10,253

The technology intangible asset is being amortized on a straight-line basis over a period of ten years, to be updated for subsequent changes in the contingent consideration that is allocated to its carrying value. The intangible asset was valued using the relief from royalty method. Significant assumptions used in the relief from royalty method include a 14.5% weighted average cost of capital and 15.0% of revenues for the royalty rate. The net book value of acquired inventories approximated its fair value. To calculate the fair value of the earnout using Monte Carlo simulations, Company projections were utilized to develop expected revenues and gross profits based on the risk inherent in the projections using the Geometric-Brownian motion for the earnout periods and related earnout payments. Significant assumptions used in the Geometric-Brownian motion analysis include projected revenues, projected gross profit, risk free rate of return of 1.6%, revenue volatility of 45.0%, and a cost of equity of 10.5%. Due to uncertainties associated with the development of a new product line and the use of estimates and assumptions to determine the fair value of the contingent consideration, the amount ultimately paid in connection with the earnout may differ from the estimated fair value at the acquisition date. A revaluation of the contingent consideration would only be required if there is a significant change to the underlying valuation assumptions. The contingent consideration will be adjusted when the contingency is resolved and the consideration is paid or becomes payable. Any difference between the cash payment and the amount accrued for contingent consideration will result in an adjustment to the technology intangible asset. Contingent consideration expected to be paid within the next year is classified as current on the condensed consolidated balance sheet.

Inventories

3 Months Ended

Mar. 31, 2022

Inventories [Abstract]

Inventories

Note 5

Inventories:

Inventories consist of the following:

	March 31, 2022		December 31, 2021
Raw materials and work-in-process	$	3,881	$	3,201
Finished goods		877		288
Total inventories	$	4,758	$	3,489

Work-in-process is immaterial, given the Company’s typically short manufacturing cycle and therefore, is included with raw materials.

Property and Equipment, net

3 Months Ended

Mar. 31, 2022

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 6

Property and Equipment, net:

Property and equipment consist of the following:

	March 31, 2022			December 31, 2021
Lasers placed-in-service	$	26,685		$	25,949
Equipment, computer hardware and software		268			238
Furniture and fixtures		218			213
Leasehold improvements		90			254
		27,261			26,654
Accumulated depreciation and amortization		(20,340	)		(19,771	)
Property and equipment, net	$	6,921		$	6,883

Depreciation and amortization expense was $625 and $481 for the three months ended March 31, 2022 and 2021, respectively.

Intangible Assets, net

3 Months Ended

Mar. 31, 2022

Intangible Assets, net [Abstract]

Intangible Assets, net

Note 7

Intangible Assets, net:

Intangible assets consist of the following as of March 31, 2022:

	Balance		Accumulated Amortization			Intangible Assets, net
Core technology	$	5,700	$	(3,848	)	$	1,852
Product technology		12,182		(2,232	)		9,950
Customer relationships		6,900		(4,658	)		2,242
Tradenames		1,500		(1,013	)		487
Pharos customer lists		5,314		(277	)		5,037
	$	31,596	$	(12,028	)	$	19,568

Intangible assets consist of the following as of December 31, 2021:

	Balance		Accumulated Amortization			Intangible Assets, net
Core technology	$	5,700	$	(3,705	)	$	1,995
Product technology		2,000		(2,000	)		-
Customer relationships		6,900		(4,485	)		2,415
Tradenames		1,500		(975	)		525
Pharos customer lists		5,314		(166	)		5,148
	$	21,414	$	(11,331	)	$	10,083

Amortization expense was $696 and $352 for the three months ended March 31, 2022 and 2021, respectively.

Definite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset group may not be recoverable. The Company recognizes an impairment loss when and to the extent that the recoverable amount of an asset group is less than its carrying value. There were no impairment charges for the three months ended March 31, 2022 or 2021.

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years:

Remaining 2022	$	2,175
2023		2,871
2024		2,871
2025		2,166
2026		1,461

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2022

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Note 8

Accrued Expenses and Other Current Liabilities:

Accrued expenses and other current liabilities consist of the following:

	March 31, 2022		December 31, 2021

Warranty obligations	$	66	$	59
Compensation and related benefits		1,992		2,052
State sales, use and other taxes		3,739		3,697
Professional fees and other		742		569
Total accrued expenses and other current liabilities	$	6,539	$	6,377

Long-term Debt

3 Months Ended

Mar. 31, 2022

Long-term Debt [Abstract]

Long-term Debt

Note 9

Long-term Debt:

Senior Term Facility

On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust, also acting as the administrative agent, and the lenders identified therein (“Senior Term Facility”). The Senior Term Facility provides for an $8.0 million senior term loan that was drawn upon by the Company upon executing the agreement. Borrowings under the Senior Term Facility bear interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and mature on September 1, 2026, unless terminated earlier. The Company is obligated to make monthly interest-only payments through September 30, 2024. From October 1, 2024 to the date of maturity, the Company will make 24 equal monthly principal payments plus interest, and all borrowings are secured by substantially all of the Company’s assets. The Senior Term Facility was amended on January 10, 2022 to provide MidCap Financial Trust’s consent to the acquisition of TheraClear Devices (Note 4).

The Company may voluntarily prepay the outstanding term loan, with such prepayment at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made within 12 months of September 30, 2021, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after September 30, 2021, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after September 30, 2021, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after September 30, 2021 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions. The Senior Term Facility also contains a number of negative covenants that subject the Company to certain exceptions and waivers and restrictions, as defined in the agreement. In addition, the Senior Term Facility contains a quarterly financial covenant that requires the Company to not have less than $24.0 million of net revenue for the trailing 12-month period as of September 30, 2021, with compliance measured on the last day of each fiscal quarter beginning on September 30, 2021. At March 31, 2022, the minimum net revenue threshold was $25.5 million. The minimum net revenue threshold will increase to $30.0 million by December 31, 2023. At March 31, 2022, the Company was in compliance with all financial and nonfinancial covenants within the Senior Term Facility.

The Senior Term Facility contains customary indemnification obligations and customary events of default, including, among other things, (i) nonpayment, (ii) breach of warranty, (iii) nonperformance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (iv) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (xi) regulatory matters, (xii) failure to remain a publicly traded company and (xiii) material adverse event. Where an event of default arises from certain bankruptcy events, the commitments shall automatically and immediately terminate and the principal of, and interest then outstanding on, all of the loans shall become immediately due and payable. Subject to certain notice requirements and other conditions, upon the occurrence of other events of default, including the occurrence of a condition having or reasonably likely to have a material adverse effect, commitments may be terminated and the principal of, and interest then outstanding on, all of the loans may become immediately due and payable. On March 31, 2022, no event of default had occurred and the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and was remote.

In connection with entering into the Senior Term Facility, the Company issued an affiliate of the lender a warrant to purchase 373,626 shares of the Company’s common stock at an initial exercise price of $1.82 per share. The warrants are equity classified and are exercisable at any time on or prior to the tenth anniversary of their issue date. The estimated fair value of the warrants was $585 and determined using the Black-Scholes option pricing model. The key assumptions used in the Black-Scholes option pricing model were (i) an expected term of ten years, (ii) expected volatility of 88.6%, (iii) a risk-free rate of 1.50% and (iv) no estimated dividend yield. In addition, the Company incurred third party costs and lender fees of $133. The proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrants and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $644 as of March 31, 2022. The Company recognized interest expense of $199 during the three months ended March 31, 2022, of which $37 was related to the amortization of the debt discount.

Future minimum principal payments at March 31, 2022 are as follows:

2024	$	1,000
2025		4,000
2026		3,000
Total	$	8,000

Stock-based Compensation

3 Months Ended

Mar. 31, 2022

Stock-based Compensation [Abstract]

Stock-based Compensation

Note 10

Stock-based Compensation:

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of March 31, 2022, there were 3,412,029 shares of common stock remaining available for issuance for awards under the 2016 Plan.

The Company measures stock‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded stock‑based compensation expense of $368 and $662 for the three months ended March 31, 2022 and 2021, respectively, and within general and administrative expenses in the accompanying condensed consolidated statements of operations.

Stock Options

The following table summarizes stock option activity for the three months ended March 31, 2022:

	Number of shares			Weighted average exercise price per share		Weighted average remaining contractual term (years)
Outstanding at January 1, 2022		3,938,613		$	1.90
Granted		860,000		$	1.45
Exercised		(15,000	)	$	1.29
Forfeited and expired		(348,899	)	$	2.97
Outstanding at March 31, 2022		4,434,714		$	1.73		8.8
Exercisable at March 31, 2022		1,396,863		$	1.94		7.5

The weighted‑average grant date fair value of options granted was $1.09 per share during the three months ended March 31, 2022. As of March 31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $3,393, which the Company expects to recognize over a weighted‑average period of approximately 2.6 years. The aggregate intrinsic value of options outstanding and options exercisable at March 31, 2022 was $39 and $1, respectively.

For the three months ended March 31, 2022, the fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:

Expected volatility	89.6	%
Risk‑free interest rate	2.4	%
Expected life (in years)	6.1
Expected dividend yield	0.0	%

On March 30, 2022, the Company granted 160,000 stock-based options to the Chief Executive Officer. The vesting of these awards is contingent upon meeting one or more financial goals (a performance condition) or a common stock share price (a market condition). The fair value of stock-based awards is determined at the date of grant. Stock-based compensation expense is recorded ratably for market condition awards during the requisite service period and is not reversed, except for forfeitures, at the vesting date regardless of whether the market condition is met. Stock-based compensation expense for performance condition awards is re-evaluated at each reporting period based on the probability of the achievement of the goal. Stock-based compensation expense related to these options is nominal for the three months ended March 31, 2022.

Restricted Stock Units

Restricted stock units have been issued to certain board members. Restricted stock units unvested are summarized in the following table:

	Number of shares			Weighted average grant date fair value
Unvested at January 1, 2022		90,540		$	1.45
Granted		9,141		$	1.47
Vested		(10,000	)	$	1.45
Unvested at March 31, 2022		89,681		$	1.45

As of March 31, 2022, the total unrecognized compensation expense related to unvested restricted stock units was $35, which the Company expects to recognize over a weighted‑average period of approximately 0.3 years.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Taxes [Abstract]
Income Taxes	Note 11 Income Taxes: The Company accounts for income taxes using the asset and liability method. The provision for income taxes includes federal, state and local income taxes currently payable and deferred taxes resulting from temporary differences between the financial statement and tax bases of assets and liabilities. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. No income tax expense was incurred for the three months ended March 31, 2022. Income tax expense of $4 for the three months ended March 31, 2021 was comprised primarily of changes in deferred tax liability related to goodwill. Goodwill is an amortizing asset according to tax regulations. The United States enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act is an approximately $2 trillion emergency economic stimulus package in response to the COVID-19 outbreak, which among other things, contains numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company analyzed the impact of the CARES Act and does not foresee a significant impact on its condensed consolidated financial position, results of operations, effective tax rate and cash flows. The Company has experienced certain ownership changes, which under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, result in annual limitations on the Company’s ability to utilize its net operating losses in the future. The February 2014, July 2014, June 2015 and May 2018 equity raises by the Company will limit the annual use of these net operating loss carryforwards. Although the Company has not performed a Section 382 study, any limitation of its pre-change net operating loss carryforwards that would result in a reduction of its deferred tax asset would also have an equal and offsetting adjustment to the valuation allowance.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Business Segments

3 Months Ended

Mar. 31, 2022

Business Segments [Abstract]

Business Segments

Note 12

Business Segments:

The Company has organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest expense and other income (expense) are also not allocated to the operating segments.

The following tables reflect results of operations from the Company’s business segments for the periods indicated below:

Three Months Ended March 31, 2022

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues, net	$	5,067		$	1,974		$	7,041
Costs of revenues		2,032			881			2,913
Gross profit		3,035			1,093			4,128
Gross profit %		59.9	%		55.4	%		58.6	%

Allocated operating expenses:
Engineering and product development		126			37			163
Selling and marketing		3,300			316			3,616
Unallocated operating expenses		-			-			2,652
		3,426			353			6,431
(Loss) income from operations		(391	)		740			(2,303	)
Interest expense		-			-			(199	)
(Loss) income before income taxes	$	(391	)	$	740		$	(2,502	)

Three Months Ended March 31, 2021

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues, net	$	4,679		$	1,148		$	5,827
Costs of revenues		1,501			613			2,114
Gross profit		3,178			535			3,713
Gross profit %		67.9	%		46.6	%		63.7	%

Allocated operating expenses:
Engineering and product development		361			23			384
Selling and marketing		2,802			130			2,932
Unallocated operating expenses		-			-			2,789
		3,163			153			6,105
Income (loss) from operations		15			382			(2,392	)
Interest expense		-			-			(30	)
Interest income		-			-			8
Income (loss) before income taxes	$	15		$	382		$	(2,414	)

The following tables present the Company’s revenue disaggregated by geographical region for the three months ended March 31, 2022 and 2021, respectively. Domestic refers to revenue from customers based in the United States, and foreign recurring revenue is derived from sales to the Company’s distributors, primarily in Asia.

Three Months Ended March 31, 2022

	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	4,689	$	695	$	5,384
Foreign		378		1,279		1,657
Total	$	5,067	$	1,974	$	7,041

Three Months Ended March 31, 2021

	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	4,426	$	258	$	4,684
Foreign		253		890		1,143
Total	$	4,679	$	1,148	$	5,827

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Significant Customer Concentration	3 Months Ended
Significant Customer Concentration	Mar. 31, 2022
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 13 Significant Customer Concentrations: For the three months ended March 31, 2022 and 2021, revenues from sales to one of the Company’s distributors were $810, or 11.5%, and $683, or 11.7%, respectively. No other customer represented more than 10% of total company revenues for the three months ended March 31, 2022 and 2021. No customer represented more than 10% of total accounts receivable as of March 31, 2022 or December 31, 2021.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 14

Commitments and Contingencies:

Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from one to three years, and one facility lease has a renewal option for two years. Renewal options have been excluded from the determination of the lease term as they are not reasonably certain of exercise.

Operating lease costs were $113 and $116 for the three months ended March 31, 2022 and 2021, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $113 and $116 for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the incremental borrowing rate was 9.76% and the weighted average remaining lease term was 2.3 years.

The following table summarizes the Company’s operating lease maturities as of March 31, 2022:

	Amount
Remaining 2022	$	258
2023		242
2024		186
Total remaining lease payments		686
Less: imputed interest		(73	)
Total lease liabilities	$	613

Accrued State Sales and Use Tax

The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the condensed consolidated statements of operations.

The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing and time period at issue, as well as the final outcome of any audit and actual settlement, remains uncertain.

In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. Several states have assessed the Company an aggregate of $2,375 including penalties and interest for the period from March 2014 through April 2020. The Company received notification that an administrative state judge issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. This ruling covers $1,484 of the total $2,375 of assessments. The jurisdiction filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022. On May 6, 2022, the Company received a written decision from Tax Appeals Tribunal (“Tribunal”) overturning the favorable sales tax determination of the administrative law judge. The Company has until September 6, 2022 to file an appeal of the Tribunal’s decision.

The Company is also in another jurisdiction’s administrative process of appeal with respect to the remaining $891 of assessments, and the timing of the process has been impacted by the COVID-19 pandemic. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties.

Milestone Payments

In January 2022, the Company entered into a Development Agreement (the “Development Agreement”) with Theravant Corporation (“Theravant”). Under the Development Agreement, the Company will reimburse Theravant for costs incurred in further developing certain TheraClear technology and other healthcare products and methods for the medical aesthetic marketplace. In connection with the development of three devices, Theravant is eligible to receive $500 upon FDA clearance for each device and $500 upon achievement of certain net revenue targets for each device, aggregating to $3,000 of potential future milestone payments under the Development Agreement. The Development Agreement has a three-year term, unless terminated sooner by either party, and is being accounted for separately from the TheraClear asset acquisition discussed in Note 4.

Legal Matters

In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony and information in connection with various aspects of its activities.

On April 1, 2022, a proposed representative class action under California’s Private Attorneys General Act (“PAGA”) was filed in Superior Court of California, County of San Diego against the Company and an employment agency which provided the Company with temporary employees. The complaint alleges various violations of the California Labor Code, including California’s wage and hour laws, relating to current and former non-exempt employees of the Company. The complaint seeks class status and payments for allegedly unpaid compensation and attorney’s fees. In a related matter, the attorneys in this matter and the proposed class representative, in a letter dated March 12, 2022, to the California Labor & Workforce Development Agency made nearly identical claims seeking the right to pursue a PAGA action against the Company and the employment agency. No amount has been accrued for this matter as of March 31, 2022.

The Company (Policies)

3 Months Ended

Mar. 31, 2022

The Company [Abstract]

Principles of Consolidation

Unaudited Interim Condensed Consolidated Financial Statements

Reclassifications

Significant Accounting Policies

Use of Estimates

Fair Value Measurements

	•	Level 1 – quoted market prices in active markets for identical assets or liabilities.
	•	Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

	Three Months Ended, March 31,
	2022			2021
Balance, beginning of period	$	79		$	113
Additions		34			4
Expirations and claimed satisfied		(14	)		(32	)
Total		99			85
Less current portion within accrued expenses and other current liabilities		(66	)		(63	)
Balance within deferred revenues and other liabilities	$	33		$	22

Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	March 31,
	2022		2021
Unvested restricted stock units		89,681		-
Stock options		4,434,714		6,925,478
Common stock warrants		373,626		-
Total		4,898,021		6,925,478

Accounting Pronouncements Recently Adopted and Not Yet Adopted

Accounting Pronouncements Recently Adopted

Recent Accounting Pronouncements Not Yet Adopted

The Company (Tables)

3 Months Ended

Mar. 31, 2022

The Company [Abstract]

Accrued Warranty Costs Activity

The activity in the warranty accrual during the three months ended March 31, 2022 and 2021 is summarized as follows:

	Three Months Ended, March 31,
	2022			2021
Balance, beginning of period	$	79		$	113
Additions		34			4
Expirations and claimed satisfied		(14	)		(32	)
Total		99			85
Less current portion within accrued expenses and other current liabilities		(66	)		(63	)
Balance within deferred revenues and other liabilities	$	33		$	22

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	March 31,
	2022		2021
Unvested restricted stock units		89,681		-
Stock options		4,434,714		6,925,478
Common stock warrants		373,626		-
Total		4,898,021		6,925,478

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2022

Revenue Recognition [Abstract]

Future Undiscounted Fixed Treatment Code Payments from International Recurring Revenue Customers

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of March 31, 2022:

Remaining 2022	$	1,263
2023		1,624
2024		1,303
2025		530
2026		4
Total	$	4,724

Acquisition of TheraClear Assets (Tables)

3 Months Ended

Mar. 31, 2022

Acquisition of TheraClear Assets [Abstract]

Purchase Price Allocation

The purchase price was allocated, on a relative fair basis, to the technology intangible asset and acquired inventories as follows:

Consideration:
Cash payment	$	500
Common stock issued		500
Transaction costs		131
Contingent consideration		9,122
Total consideration	$	10,253

Assets acquired:
Technology intangible asset	$	10,182
Inventories		71
Total assets acquired	$	10,253

Inventories (Tables)

3 Months Ended

Mar. 31, 2022

Inventories [Abstract]

Inventories

Inventories consist of the following:

	March 31, 2022		December 31, 2021
Raw materials and work-in-process	$	3,881	$	3,201
Finished goods		877		288
Total inventories	$	4,758	$	3,489

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2022

Property and Equipment, net [Abstract]

Components of Property and Equipment

Property and equipment consist of the following:

	March 31, 2022			December 31, 2021
Lasers placed-in-service	$	26,685		$	25,949
Equipment, computer hardware and software		268			238
Furniture and fixtures		218			213
Leasehold improvements		90			254
		27,261			26,654
Accumulated depreciation and amortization		(20,340	)		(19,771	)
Property and equipment, net	$	6,921		$	6,883

Intangible Assets, net (Tables)

3 Months Ended

Mar. 31, 2022

Intangible Assets, net [Abstract]

Components of Intangible Assets

Intangible assets consist of the following as of March 31, 2022:

	Balance		Accumulated Amortization			Intangible Assets, net
Core technology	$	5,700	$	(3,848	)	$	1,852
Product technology		12,182		(2,232	)		9,950
Customer relationships		6,900		(4,658	)		2,242
Tradenames		1,500		(1,013	)		487
Pharos customer lists		5,314		(277	)		5,037
	$	31,596	$	(12,028	)	$	19,568

Intangible assets consist of the following as of December 31, 2021:

	Balance		Accumulated Amortization			Intangible Assets, net
Core technology	$	5,700	$	(3,705	)	$	1,995
Product technology		2,000		(2,000	)		-
Customer relationships		6,900		(4,485	)		2,415
Tradenames		1,500		(975	)		525
Pharos customer lists		5,314		(166	)		5,148
	$	21,414	$	(11,331	)	$	10,083

Estimated Future Amortization Expense for Intangible Assets

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years:

Remaining 2022	$	2,175
2023		2,871
2024		2,871
2025		2,166
2026		1,461

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2022

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	March 31, 2022		December 31, 2021

Warranty obligations	$	66	$	59
Compensation and related benefits		1,992		2,052
State sales, use and other taxes		3,739		3,697
Professional fees and other		742		569
Total accrued expenses and other current liabilities	$	6,539	$	6,377

Long-term Debt (Tables)

3 Months Ended

Mar. 31, 2022

Long-term Debt [Abstract]

Future Minimum Principal Payments

Future minimum principal payments at March 31, 2022 are as follows:

2024	$	1,000
2025		4,000
2026		3,000
Total	$	8,000

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Stock-based Compensation [Abstract]

Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2022:

	Number of shares			Weighted average exercise price per share		Weighted average remaining contractual term (years)
Outstanding at January 1, 2022		3,938,613		$	1.90
Granted		860,000		$	1.45
Exercised		(15,000	)	$	1.29
Forfeited and expired		(348,899	)	$	2.97
Outstanding at March 31, 2022		4,434,714		$	1.73		8.8
Exercisable at March 31, 2022		1,396,863		$	1.94		7.5

Weighted Average Assumption Used for Grant Date Fair Value of Option Grants

For the three months ended March 31, 2022, the fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:

Expected volatility	89.6	%
Risk‑free interest rate	2.4	%
Expected life (in years)	6.1
Expected dividend yield	0.0	%

Summary of Restricted Stock Unit Unvested

Restricted stock units have been issued to certain board members. Restricted stock units unvested are summarized in the following table:

	Number of shares			Weighted average grant date fair value
Unvested at January 1, 2022		90,540		$	1.45
Granted		9,141		$	1.47
Vested		(10,000	)	$	1.45
Unvested at March 31, 2022		89,681		$	1.45

Business Segments (Tables)

3 Months Ended

Mar. 31, 2022

Business Segments [Abstract]

Segment Reporting Information by Segment

The following tables reflect results of operations from the Company’s business segments for the periods indicated below:

Three Months Ended March 31, 2022

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues, net	$	5,067		$	1,974		$	7,041
Costs of revenues		2,032			881			2,913
Gross profit		3,035			1,093			4,128
Gross profit %		59.9	%		55.4	%		58.6	%

Allocated operating expenses:
Engineering and product development		126			37			163
Selling and marketing		3,300			316			3,616
Unallocated operating expenses		-			-			2,652
		3,426			353			6,431
(Loss) income from operations		(391	)		740			(2,303	)
Interest expense		-			-			(199	)
(Loss) income before income taxes	$	(391	)	$	740		$	(2,502	)

Three Months Ended March 31, 2021

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			TOTAL
Revenues, net	$	4,679		$	1,148		$	5,827
Costs of revenues		1,501			613			2,114
Gross profit		3,178			535			3,713
Gross profit %		67.9	%		46.6	%		63.7	%

Allocated operating expenses:
Engineering and product development		361			23			384
Selling and marketing		2,802			130			2,932
Unallocated operating expenses		-			-			2,789
		3,163			153			6,105
Income (loss) from operations		15			382			(2,392	)
Interest expense		-			-			(30	)
Interest income		-			-			8
Income (loss) before income taxes	$	15		$	382		$	(2,414	)

Disaggregation of Revenue by Geographical Region

Three Months Ended March 31, 2022

	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	4,689	$	695	$	5,384
Foreign		378		1,279		1,657
Total	$	5,067	$	1,974	$	7,041

Three Months Ended March 31, 2021

	Dermatology Recurring Procedures		Dermatology Procedures Equipment		TOTAL
Domestic	$	4,426	$	258	$	4,684
Foreign		253		890		1,143
Total	$	4,679	$	1,148	$	5,827

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of March 31, 2022:

	Amount
Remaining 2022	$	258
2023		242
2024		186
Total remaining lease payments		686
Less: imputed interest		(73	)
Total lease liabilities	$	613

The Company, Background (Details) - XTRAC [Member]	3 Months Ended
The Company, Background (Details) - XTRAC [Member]	Mar. 31, 2022 Systems
United States [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Number of systems placed in dermatologists offices	903
International [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Number of systems placed in dermatologists offices	55

The Company, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Activity of Warranty Accrual [Roll Forward]
Balance, beginning of year	$ 79	$ 113
Additions	34	4
Expirations and claims satisfied	(14)	(32)
Total	99	85
Less current portion within accrued expenses and other current liabilities	(66)	(63)	$ (59)
Balance within deferred revenues and other liabilities	$ 33	$ 22
Minimum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	2 years
Offered warranty period	4 years

The Company, Earnings Per Share (Details) - shares	3 Months Ended
The Company, Earnings Per Share (Details) - shares	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	4,898,021	6,925,478
Unvested Restricted Stock Units [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	89,681	0
Stock Options [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	4,434,714	6,925,478
Common Stock Warrants [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	373,626	0

Liquidity (Details) $ in Millions	1 Months Ended
Liquidity (Details) $ in Millions	Oct. 31, 2021 USD ($)
At-the-Market Equity Offering [Member] \| Maximum [Member]
Equity Distribution Agreement [Abstract]
Amount of common stock the Company may sell under equity distribution agreement	$ 11.0

Revenue Recognition, Remaining Performance Obligation (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 21
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 10
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	3 years

Revenue Recognition, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Treatment Equipment [Abstract]
Lease term	36 months
Contract with Customer, Liability [Abstract]
Short-term contract liabilities	$ 10
Long-term contract liabilities	11
Change in Contract with Customer, Liability [Abstract]
Contract liabilities recognized as revenue	$ 5	$ 34
Minimum [Member]
Treatment Equipment [Abstract]
Notice period to cancel contract agreement	30 days
Maximum [Member]
Treatment Equipment [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Treatment Equipment [Abstract]
Lease term	48 months

Revenue Recognition, Future Undiscounted Fixed Payments from International Recurring Revenue Customers (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 21
International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	4,724
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 10
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,263
Expected timing of satisfaction period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,624
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,303
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 530
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 \| International [Member]
Remaining Performance Obligation [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 4
Expected timing of satisfaction period	1 year

Acquisition of TheraClear Assets (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2022	Mar. 31, 2022
Acquisition of Assets and Liabilities [Abstract]
Aggregate value of common stock issued in connection with asset acquisition		$ 500
Maximum [Member]
Acquisition of Assets and Liabilities [Abstract]
Future earnout milestone payments	$ 500
Future milestone payments	3,000
Maximum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Future royalty payments	500
TheraClear Corporation [Member]
Acquisition of Assets and Liabilities [Abstract]
Upfront cash payment	$ 500
Number of shares issued in connection with asset acquisition (in shares)	358,367
Aggregate value of common stock issued in connection with asset acquisition	$ 500
Consideration [Abstract]
Cash payment	500
Common stock issued	500
Transaction costs	131
Contingent consideration	9,122
Total consideration	10,253
Assets acquired [Abstract]
Inventories	71
Total assets acquired	$ 10,253
Weighted average cost of capital	14.50%
Revenues for the royalty rate	15.00%
Risk free rate of return	1.60%
Revenue volatility	45.00%
Cost of equity	10.50%
TheraClear Corporation [Member] \| Technology [Member]
Assets acquired [Abstract]
Intangible asset	$ 10,182
Amortization period of intangible assets		10 years
TheraClear Corporation [Member] \| Foreign [Member]
Acquisition of Assets and Liabilities [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	25.00%
Subsequent period of gross profit for future royalty payments		4 years
TheraClear Corporation [Member] \| Minimum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	10.00%
TheraClear Corporation [Member] \| Maximum [Member]
Acquisition of Assets and Liabilities [Abstract]
Future earnout milestone payments	$ 3,000
Future milestone payments	1,000
TheraClear Corporation [Member] \| Maximum [Member] \| Domestic [Member]
Acquisition of Assets and Liabilities [Abstract]
Future royalty payments	$ 20,000
Percentage of gross profit for future royalty payments for subsequent period	20.00%

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Schedule of inventory [Abstract]
Raw materials and work in process	$ 3,881	$ 3,201
Finished goods	877	288
Total inventories	$ 4,758	$ 3,489

Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 27,261		$ 26,654
Accumulated depreciation and amortization	(20,340)		(19,771)
Property and equipment, net	6,921		6,883
Depreciation and amortization expense	625	$ 481
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	26,685		25,949
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	268		238
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	218		213
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 90		$ 254

Intangible Assets, net (Details) - USD ($) $ in Thousands	3 Months Ended
Intangible Assets, net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Balance	$ 31,596		$ 21,414
Accumulated amortization	(12,028)		(11,331)
Intangible assets, net	19,568		10,083
Amortization expense of intangible assets	696	$ 352
Impairment of intangible assets	0	$ 0
Estimated amortization expense [Abstract]
Remaining 2022	2,175
2023	2,871
2024	2,871
2025	2,166
2026	1,461
Core Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	5,700		5,700
Accumulated amortization	(3,848)		(3,705)
Intangible assets, net	1,852		1,995
Product Technology [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	12,182		2,000
Accumulated amortization	(2,232)		(2,000)
Intangible assets, net	9,950		0
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	6,900		6,900
Accumulated amortization	(4,658)		(4,485)
Intangible assets, net	2,242		2,415
Tradenames [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	1,500		1,500
Accumulated amortization	(1,013)		(975)
Intangible assets, net	487		525
Pharos Customer Lists [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Balance	5,314		5,314
Accumulated amortization	(277)		(166)
Intangible assets, net	$ 5,037		$ 5,148

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Warranty obligations	$ 66	$ 59	$ 63
Compensation and related benefits	1,992	2,052
State sales, use and other taxes	3,739	3,697
Professional fees and other	742	569
Total accrued expenses and other current liabilities	$ 6,539	$ 6,377

Long-term Debt, Senior Term Facility (Details) - MidCap Financial Trust [Member] - Senior Term Facility [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) Payment $ / shares shares	Sep. 30, 2021 USD ($)
Long-term Debt [Abstract]
Face amount of debt	$ 8,000
Maturity date	Sep. 01, 2026
Number of monthly principal payments plus interest \| Payment	24
Frequency of payment	monthly
Notice period	30 days
Prepayment fee if prepayment is made within twelve months	4.00%
Prepayment fee if prepayment is made between twelve months and twenty-four months	3.00%
Prepayment fee if prepayment is made between twenty-four months and thirty-six months	2.00%
Prepayment fee if prepayment is made after thirty-six months	1.00%
Minimum net revenue threshold	$ 25,500	$ 24,000
Minimum net revenue threshold by December 31, 2023	30,000
Estimated fair value of warrants	585
Third party costs and lender fees	133
Unamortized debt discount	644
Interest expense	199
Amortization of debt discount	37
Minimum [Member]
Long-term Debt [Abstract]
Prepayment of debt	$ 5,000
Common Stock [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares	373,626
Warrants, exercise price (in dollars per share) \| $ / shares	$ 1.82
LIBOR [Member]
Long-term Debt [Abstract]
Interest rate floor	0.50%
Basis spread on variable rate	7.50%
Expected Term [Member]
Long-term Debt [Abstract]
Warrants, expected term	10 years
Expected Volatility [Member]
Long-term Debt [Abstract]
Warrants, measurement input	0.886
Risk-Free Rate [Member]
Long-term Debt [Abstract]
Warrants, measurement input	0.0150
Estimated Dividend Yield [Member]
Long-term Debt [Abstract]
Warrants, measurement input	0

Long-term Debt, Future Minimum Principal Payments (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Future Payments for Long-Term Debt [Abstract]
2024	$ 1,000
2025	4,000
2026	3,000
Total	$ 8,000

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Stock-based Compensation, Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock-based Compensation [Abstract]
Stock-based compensation expense	$ 368	$ 662
2016 Omnibus Incentive Plan [Member]
Stock-based Compensation [Abstract]
Common stock reserved for future issuance (in shares)	7,832,651
Number of shares available for issuance (in shares)	3,412,029

Stock-based Compensation, Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
	Mar. 30, 2022	Mar. 31, 2022
Weighted average remaining contractual term [Abstract]
Exercisable		3 months 18 days
Unrecognized compensation expense		$ 35
Stock Options [Member]
Number of shares [Abstract]
Outstanding at beginning period (in shares)		3,938,613
Granted (in shares)		860,000
Exercised (in shares)		(15,000)
Forfeited and expired (in shares)		(348,899)
Outstanding at end of period (in shares)		4,434,714
Exercisable at end of period (in shares)		1,396,863
Weighted average exercise price per share [Abstract]
Outstanding at beginning of period (in dollars per share)		$ 1.90
Granted (in dollars per share)		1.45
Exercised (in dollars per share)		1.29
Forfeited and expired (in dollars per share)		2.97
Outstanding at end of period (in dollars per share)		1.73
Exercisable at end of period (in dollars per share)		$ 1.94
Weighted average remaining contractual term [Abstract]
Outstanding		8 years 9 months 18 days
Exercisable		7 years 6 months
Weighted-average grant date fair value (in dollars per share)		$ 1.09
Unrecognized compensation expense		$ 3,393
Unrecognized compensation expense, weighted average period		2 years 7 months 6 days
Aggregate intrinsic value of options outstanding		$ 39
Aggregate intrinsic value of options exercisable		$ 1
Stock Options [Member] \| Chief Executive Officer [Member]
Number of shares [Abstract]
Granted (in shares)	160,000

Stock-based Compensation, Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2022
Fair Value Assumptions [Abstract]
Expected volatility	89.60%
Risk-free interest rate	2.40%
Expected life (in years)	6 years 1 month 6 days
Expected dividend yield	0.00%

Stock-based Compensation, Restricted Stock Units (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
Unrecognized Compensation Expense [Abstract]
Unrecognized compensation expense \| $	$ 35
Weighted average period of recognition	3 months 18 days
Restricted Stock Units [Member]
Number of shares [Abstract]
Unvested at beginning of period (in shares) \| shares	90,540
Granted (in shares) \| shares	9,141
Vested (in shares) \| shares	(10,000)
Unvested at end of period (in shares) \| shares	89,681
Weighted average grant date fair value [Abstract]
Unvested at beginning of period (in dollars per share) \| $ / shares	$ 1.45
Granted (in dollars per share) \| $ / shares	1.47
Vested (in dollars per share) \| $ / shares	1.45
Unvested at end of period (in dollars per share) \| $ / shares	$ 1.45

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Abstract]
Income tax expense	$ 0	$ 4

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Business Segments (Details) $ in Thousands	3 Months Ended
Business Segments (Details) $ in Thousands	Mar. 31, 2022 USD ($) Segment	Mar. 31, 2021 USD ($)
Business Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues, net	$ 7,041	$ 5,827
Costs of revenues	2,913	2,114
Gross profit	$ 4,128	$ 3,713
Gross profit %	58.60%	63.70%
Allocated operating expenses [Abstract]
Engineering and product development	$ 163	$ 384
Selling and marketing	3,616	2,932
Unallocated operating expenses	2,652	2,789
Total operating expenses	6,431	6,105
Loss from operations	(2,303)	(2,392)
Interest expense	(199)	(30)
Interest income	0	8
Income (loss) before income taxes	(2,502)	(2,414)
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	7,041	5,827
Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	5,384	4,684
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	5,384	4,684
Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	1,657	1,143
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	1,657	1,143
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	5,067	4,679
Costs of revenues	2,032	1,501
Gross profit	$ 3,035	$ 3,178
Gross profit %	59.90%	67.90%
Allocated operating expenses [Abstract]
Engineering and product development	$ 126	$ 361
Selling and marketing	3,300	2,802
Unallocated operating expenses	0	0
Total operating expenses	3,426	3,163
Loss from operations	(391)	15
Interest expense	0	0
Interest income		0
Income (loss) before income taxes	(391)	15
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	5,067	4,679
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	1,974	1,148
Costs of revenues	881	613
Gross profit	$ 1,093	$ 535
Gross profit %	55.40%	46.60%
Allocated operating expenses [Abstract]
Engineering and product development	$ 37	$ 23
Selling and marketing	316	130
Unallocated operating expenses	0	0
Total operating expenses	353	153
Loss from operations	740	382
Interest expense	0	0
Interest income		0
Income (loss) before income taxes	740	382
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	1,974	1,148
Operating Segments [Member] \| Domestic [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	4,689	4,426
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	4,689	4,426
Operating Segments [Member] \| Domestic [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	695	258
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	695	258
Operating Segments [Member] \| Foreign [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	378	253
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	378	253
Operating Segments [Member] \| Foreign [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues, net	1,279	890
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues, net	$ 1,279	$ 890

Significant Customer Concentration (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Concentration Risk [Abstract]
Revenues, net	$ 7,041	$ 5,827
Revenue [Member] \| Customer Concentration Risk [Member] \| Distributor One [Member]
Concentration Risk [Abstract]
Revenues, net	$ 810		$ 683
Concentration risk percentage	11.50%		11.70%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Distributor One [Member]
Concentration Risk [Abstract]
Revenues, net	$ 0		$ 0

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Jan. 31, 2022 USD ($) Device	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Lessee, Operating Lease, Description [Abstract]
Operating lease costs		$ 113	$ 116
Cash paid for amounts included in measurement of operating lease liabilities		$ 113	$ 116
Incremental borrowing rate		9.76%
Weighted average remaining lease term		2 years 3 months 18 days
Operating Lease Maturities [Abstract]
Remaining 2022		$ 258
2023		242
2024		186
Total remaining lease payments		686
Less: imputed interest		(73)
Total lease liabilities		$ 613
Milestone Payments [Abstract]
Development agreement term		3 years
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term		1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term		3 years
Milestone Payments [Abstract]
Number of devices in development \| Device	3
Future earnout payments	$ 500
Future milestone payments	3,000
Domestic [Member] \| Maximum [Member]
Milestone Payments [Abstract]
Future royalty payments	$ 500
Tax Period from March 2014 through April 2020 [Member]
Sales and Use Tax Matters [Abstract]
Estimated tax positions subject to audit		$ 2,375
Tax Period from March 2014 through April 2020 [Member] \| Assessment One [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount		1,484
Tax Period from March 2014 through April 2020 [Member] \| Assessment Two [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount		$ 891
Facility One [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term		2 years